Impact of COVID-19 on Rheumatic Disease Outcomes

The emergence of COVID-19 has markedly influenced the clinical course of rheumatic and other immune‐mediated inflammatory diseases. Patients with these conditions face a complex balance between infection risk, immune dysregulation and the need for ongoing immunosuppression. Data from global registries and cohort studies indicate that advanced age, male sex, uncontrolled disease activity and specific comorbidities such as cardiovascular or chronic lung disease heighten the risk of hospitalisation, mechanical ventilation and death. Conversely, targeted cytokine inhibitors may confer partial protection from severe infection, while high‐dose glucocorticoids appear to increase vulnerability. Mechanistic investigations reveal that SARS-CoV-2 can amplify joint inflammation and autoantibody production, suggesting direct aggravation of rheumatic pathology. Impaired vaccine responses in systemic autoimmune disorders have also been documented, underscoring the need for tailored immunisation schedules. Collectively, these insights inform clinical guidelines that strive to optimise disease control without compromising antiviral defence.

Research from Nature Portfolio

Analysis of serological responses in patients receiving cytokine inhibitors demonstrated a lower prevalence of SARS-CoV-2 antibody development than in untreated patients with similar exposure. This seminal study revealed that blockade of tumour necrosis factor and interleukin pathways not only mitigates baseline inflammation but may also reduce viral entry or replication, offering a dual benefit in immune-mediated disorders. These findings support the notion that certain biologic agents can modulate the host–virus interface without compromising overall disease management, and they have prompted further exploration of cytokine blockade as both a rheumatic and antiviral strategy.

Impact of COVID-19 on Rheumatic Disease Outcomes publication trend

The graph below shows the total number of articles in impact of covid-19 on rheumatic disease outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Immune-mediated inflammatory disease (IMID): A disorder characterised by dysregulated immune responses causing chronic inflammation in tissues such as joints, gut or skin.

Disease-modifying antirheumatic drug (DMARD): A medication that slows or alters the underlying processes of autoimmune diseases rather than merely relieving symptoms.

Seroconversion: The development of detectable specific antibodies in the blood following infection or vaccination.

Cytokine: A small protein released by immune cells that mediates and regulates inflammation and immune responses.

Comorbidity: The presence of one or more additional medical conditions co-occurring with a primary disease, often influencing prognosis and treatment.

References

1. Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system. The Lancet Digital Health (2024).
2. SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell Communication and Signaling (2023).
3. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases (2021).
4. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications (2020).
5. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open (2021).
6. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Research & Therapy (2020).
7. Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus. JCI Insight (2024).